Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 104-110 , May 2005

Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide

Received 18 February 2004 ,Revised 21 June 2004 ,Accepted 8 September 2004.

References 

  1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laaksso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without previous myocardial infarction: implications for treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction. N. Engl. J. 1998;339:229–234
  2. Watanabe I, Kawamura I, Satoh K, Nagao K, Kushiro T, Kanmatsuse K. Effect of insulin resistance on the endothelial vasomotor function of the coronary artery of non-diabetic patients. Jpn. Circ. J. 1999;63:589–592
  3. Lehmann ED, Riley WA, Clarkson P, Gosling RG. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet. 1997;350(Suppl. II):14–19
  4. Tsushima M, Koh H, Suzuki M, Kyotani S, Waki M, Nishioeda Y, et al. Non-invasive quantitative evaluation of early atherosclerosis and the effect of monatepil, a new antihypertensive agent. An interim report. Am. J. Hypertens. 1994;7:154S–160S
  5. McVeigh GE, Brennan G, Hayes R, Cohn J, Finkelstein S, Johnston D. Vascular abnormalities in non-insulin dependent diabetes mellitus identified by arterial waveform analysis. Am. J. Med. 1993;95:424–430
  6. Levy JC, Matthews DR, Hermans MP. Correct homeosis model assessment (HOMA) uses the computer program. Diabetes Care. 1998;21:2191–2192
  7. Asmar R, Topoucian J, Pannier B, Benetos A, Safar M. on behalf of the Scientific, Quality Control, Coordination and Investigation Commitees of the Complior Study. Pulse wave velocity as endopoint in large-scale intervention trial. The compliter study. J. Hypertens. 2001;19:813–818
  8. Maarek B, Simon AC, Levenson J, Pithos-Merli I, Bouthier J. Heterogeneity of the atherosclerotic processin systemic hypertension poorly controlled by drug treatment. Am. J. Cardiol. 1998;59:414–417
  9. Lehmann ED, Rily WA, Clarkson P, Gosling RG. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet. 1997;350(Suppl. I):14–19
  10. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation. 2002;106:2085–2090
  11. Norhammer A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glicose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140–2144
  12. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekigawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagawa Diabetes Study. Diabetes Care. 1999;22:920–924
  13. The Bypass Angioplasty Revascularization Investigation Investigator . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation. 1997;96:1761–1769
  14. The Diabetes control, complications trial (DCCT) Research Group . Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am. J. Cardiol. 1995;75:894–903
  15. United Kingdom Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet. 1998;352:837–853
  16. Stratton IM, Adler AI, Neil A, Matthews DR, Manley SE, Cull CA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–421
  17. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, et al. Improved glycemic and enhanced insulin sensitivity in type 2 diabetes subjects treated with Pioglitazon. Diabetes Care. 2001;24:710–719
  18. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:517–523
  19. Ricote M, Lie AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82
  20. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of Pioglitazon in type 2 diabetic patients irrespective of the responsiveness to its antidiabetc effect. Diabetes Care. 2003;26:2493–2499
  21. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, et al. Oral administration of tetra-hydrobioprotein prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ. Res. 2000;87:566–573
  22. Shinozaki K, Hirayama A, Nishio Y, Toshida Y, Ohtani T, Okamura T, et al. Coronary endothelial dysfunction in the insulin-resistance state is linked to abnormal pteridine metabolism and oxidative stress. J. Am. Coll. Cardiol. 2001;38:1821–1828
  23. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma 2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commum. 2000;271:212–216
  24. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2000;106:629–631

PII: S0168-8227(04)00298-0

doi: 10.1016/j.diabres.2004.09.013

Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 104-110 , May 2005

Article Tools

* Image Usage & Resolution